INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, vol.75, 2021 (SCI-Expanded)
Aim of the Study Interferon-beta (IFN-beta), multiple sclerosis (MS) drug for years, does not have therapeutic effects on each patient. Yet, a considerable portion has experienced no therapeutic response to IFN-beta. Therefore, it is necessary to determine disease-specific biomarkers that affect drug response. Here, we aimed to determine the effects of interleukin 10 (IL10) and 23 (IL23A), as well as forkhead box P3 (FOXP3) genes on MS after IFN-beta therapy.